Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors

• Main Authors: Kentaro Minami (Author), Yoshinari Shinsato (Author), Masatatsu Yamamoto (Author), Homare Takahashi (Author), Shaoxuan Zhang (Author), Yukihiko Nishizawa (Author), Sho Tabata (Author), Ryuji Ikeda (Author), Kohich Kawahara (Author), Kazutake Tsujikawa (Author), Kazuo Chijiiwa (Author), Katsushi Yamada (Author), Shin-ichi Akiyama (Author), Sandra Pérez-Torras (Author), Marcal Pastor-Anglada (Author), Tatsuhiko Furukawa (Author), Takeda Yasuo (Author)
• Format: Book
• Published: Elsevier, 2015-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Gemcitabine is widely used for pancreatic, lung, and bladder cancer. However, drug resistance against gemcitabine is a large obstacle to effective chemotherapy. Nucleoside transporters, nucleoside and nucleotide metabolic enzymes, and efflux transporters have been reported to be involved in gemcitab...